Is sexual desire a matter of medicine?

That was the question back in 2015, when Addyi won a controversial FDA approval to treat hypoactive sexual desire disorder, or HSDD. Now, the FDA is considering a similar drug from AMAG Pharmaceuticals — one that the company hopes can succeed where Sprout Pharmaceuticals largely did not.

But some experts see AMAG’s drug, bremelanotide, as yet another overreach from the pharmaceutical industry, an effort to reduce the complexity of human sexuality to a set of measurable dots on a chart. And then there’s Wall Street, which, mindful of Addyi’s commercial failure, has little in the way of optimism for bremelanotide's future.

An FDA decision could come as soon as Friday.

Read more.